US: Pharma firm appeals to Supreme Court over abortion pill mail ban

In the United States, the pharmaceutical company Danco Laboratories is taking its fight to the Supreme Court, seeking to overturn a recent decision that restricts access to the abortion pill mifepristone. The appeals court's ruling, which halts mail-order delivery and mandates in-person dispensing, is seen by Danco as a direct threat to timely medical care. The company argues that this abrupt change creates significant confusion for patients and providers alike, potentially leading to severe health consequences. This legal maneuver is part of a broader, ongoing struggle over reproductive rights in America, intensified since the Supreme Court's 2022 decision to overturn Roe v. Wade. While some states have moved to ban or severely restrict abortion, others are working to protect access. Danco's intervention highlights the critical role of medication abortion and the legal battles shaping its availability. From our perspective, this case underscores the deep divisions within the US on reproductive healthcare and the complex legal landscape that patients must navigate.

“

Das Urteil sorgt für »sofortige Verwirrung« bei zeitkritischen medizinischen Entscheidungen, heißt es in dem Antrag.